Table 1 JAK1 and JAK3-selective inhibitors currently in clinical studies
From: JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
Name | Selectivity | Patient group | Clinical phase |
|---|---|---|---|
Baricitinib (LY3009104) | JAK1/2 | Rheumatoid arthritis | Phase 3 |
Psoriasis | |||
Ruxolitinib (INCB18424) | JAK1/2 | Acute leukemia | Phase 1/2 |
Chronic myeloid leukemia (CML) | |||
Acute myeloid leukemia (AML) | FDA approved | ||
Myelofibrosis | |||
Decernotinib (VX-509) | JAK3 | Rheumatoid arthritis | Phase 2/3 |
Tofacitinib (CP-690550) | JAK3 | Rheumatoid arthritis | FDA approved |
INCB039110 | JAK1 | Primary myelofibrosis | Phase 2 |
Post-polycythemia vera fibrosis | |||
Post-essential thrombocythemia myelofibrosis | |||
PF-04965842 | JAK1 | Plaque psoriasis | Phase 2 |
Filgotinib (GLPG0634) | JAK1 | Rheumatoid arthritis | Phase 2 |
Crohn’s disease | |||
INCB047986 | JAK1 | Rheumatoid arthritis | Phase 2 |
Momelotinib (CYT387) | JAK1/JAK2 | Primary myelofibrosis | Phase 1/2 |
Post-polycythemia vera myelofibrosis | Phase 2 | ||
Post-essential thrombocythemia myelofibrosis | |||
Polycythemia vera | |||
Essential thrombocythemia | Phase 2 | ||
GSK2586184 | JAK1 | Psoriasis | Phase 2 |
Systemic lupus erythematosus | |||
AT9283 | JAK2/JAK3 | Multiple myeloma | Phase 2 |
Acute myeloid leukemia | Phase 1/2 | ||
Acute lymphoblastic leukemia | |||
Chronic myeloid leukemia | |||
Myelodysplastic syndromes | |||
Myelofibrosis |